2026 Interim report
Filed with HKEX · Stock code 6833 · · 66 pages · English and Chinese
2 Corporate Information公司資料 4 Financial Highlights財務摘要 6 Corporate Profile公司簡介 7 Management Discussion and Analysis管理層討論及分析 21 Other Information其他资料 30 Independent Review Report獨立審閱報告 32 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income簡明綜合損益及其他全面收益表 33 Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表 35 Condensed Consolidated Statement of Changes in
Sinco Pharmaceuticals Holdings Ltd. on 6ix
Earlier from Sinco Pharmaceuticals
- Sinco Pharmaceuticals Holdings: Proposals for general mandates to issue shares and repurchase shares, re-election of directors and notice of annual general meeting
- Change of joint company secretary change of authorised representative and waiver from strict compliance with rules 3.28 and 8.17 of the listing rules
Later from Sinco Pharmaceuticals
All Sinco Pharmaceuticals news releasesFollow Sinco Pharmaceuticals into a list and get an email when it puts out news.
Follow Sinco Pharmaceuticals